VEGFA and glioma: Immunotherapy inhibits the immune checkpoint receptor of programmed cell protein 1 (PD-1), and bevacizumab that inhibits the vascular endothelial growth factor is now being studied to enhance the treatment outcome of patients treated with GBM, which is the most prevalent glioma type (8).